Loading…
Special Diabetes Program Reauthorization Act of 2023
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
88pct
50d open
vs 5,649 other S bills in the 118th — cohort avg 33d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2024 · fourth_quarter · Health Issues
S. 4504/H.R. 8698 - SCREEN for Type 1 Diabetes Act (A bill to amend the Public Health Service Act to provide for a public awareness campaign with respect to screening for type 1 diabetes, and for other purposes). S. 1855/H.R. 2550 - Special Diabetes Program Reauthorization Act of 2023. S. 1269 - INSULIN Act of 2023. H.R. 4758/S.2372 - Accelerating Kids Access to Care Act (AKAC). S. 3234 - Chronic Disease Flexible Coverage Act.
Client expense: $180,000 · Firm income: Not reported
Placed on Senate Legislative Calendar under General Orders. Calendar No. 184.
Committee on Health, Education, Labor, and Pensions. Reported by Senator Sanders without amendment. Without written report.
Committee on Health, Education, Labor, and Pensions. Ordered to be reported without amendment favorably.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2008-2009)
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
S. 4504/H.R. 8698 - SCREEN for Type 1 Diabetes Act S. 1855/H.R. 2550 - Special Diabetes Program Reauthorization Act of 2023 S. 1269 - INSULIN Act of 2023 H.R. 4758/S.2372, Accelerating Kids Access to Care Act (AKAC) S. 3234, Chronic Disease Flexible Coverage Act
Client expense: Not reported · Firm income: $80,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · third_quarter · Health Issues
-S. 4504 / H.R 8698 - SCREEN for Type 1 Diabetes Act (A bill to amend the Public Health Service Act to provide for a public awareness campaign with respect to screening for type 1 diabetes, and for other purposes) -S. 1855 - Special Diabetes Program Reauthorization Act of 2023 -S. 1269 - INSULIN Act of 2023 -H.R 1499 - Affordable Insulin Now Act -S. 954 - Affordable Insulin Now Act of 2023 -H.R. 3800 - Chronic Disease Flexible Coverage Act -Issues related to cell and gene therapies
Client expense: $140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
S.1269 - INSULIN Act of 2023 S.1855 Special Diabetes Program Reauthorization Act of 2023 S.4504/H.R.8698 Strengthening Collective Resources for Encouraging Education Needed (SCREEN) for Type 1 Diabetes Act Issues related to insulin affordability and cell and gene therapies
Client expense: Not reported · Firm income: $80,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · second_quarter · Health Issues
-H.R 8698, SCREEN for Type 1 Diabetes Act (A bill to amend the Public Health Service Act to provide for a public awareness campaign with respect to screening for type 1 diabetes, and for other purposes). -S. 4504, SCREEN Act (A bill to amend the Public Health Service Act to provide for a public awareness campaign with respect to screening for type 1 diabetes, and for other purposes). -S. 1269, INSULIN Act of 2023. -S. 1855, Special Diabetes Program Reauthorization Act of 2023. -H.R. 2550, Special Diabetes Program Reauthorization Act of 2023. -H.R 1499, Affordable Insulin Now Act. -S. 954, Affordable Insulin Now Act of 2023. -H.R. 5378, Lower Costs, More Transparency Act. -H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act of 2023. -Issues related to cell and gene therapies.
Client expense: $370,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
S. 1269 - INSULIN Act of 2023 S. 1855 Special Diabetes Program Reauthorization Act of 2023 Strengthening Collective Resources for Encouraging Education Needed (SCREEN) for Type 1 Diabetes Act Issues related to insulin affordability
Client expense: Not reported · Firm income: $80,000
2024 · first_quarter · Health Issues
S. 1269 - INSULIN Act of 2023 S. 1855 Special Diabetes Program Reauthorization Act of 2023 Issues related to insulin affordability
Client expense: Not reported · Firm income: $80,000
2024 · first_quarter · Health Issues
Implementation of the special diabetes program, renewal of the special diabetes program, artificial pancreas program, NIH, innovation in drug development for diabetes, insulin access and affordability H.R. 5378 Lower Costs, More Transparency Act S. 1269 - INSULIN Act of 2023 S. 1855 Special Diabetes Program Reauthorization Act of 2023
Client expense: Not reported · Firm income: $80,000
2023 · fourth_quarter · Health Issues
Implementation of the special diabetes program, renewal of the special diabetes program, artificial pancreas program, NIH, innovation in drug development for diabetes, insulin access and affordability H.R. 5378 Lower Costs, More Transparency Act S. 1269 - INSULIN Act of 2023 S. 1855 Special Diabetes Program Reauthorization Act of 2023
Client expense: Not reported · Firm income: $80,000
2023 · second_quarter · Health Issues
H.R. 2547 - Special Diabetes Program for Indians Reauthorization Act of 2023 H.R. 2550 - Special Diabetes Program Reauthorization Act of 2023 S. 1855 - Special Diabetes Program Reauthorization Act of 2023 S. 1269 - INSULIN Act of 2023 H.R. 1488 - Affordable Insulin Now Act S. 954 - Affordable Insulin Now Act H.R. 3561 - PATIENT Act of 2023 Issues related to insulin affordability Issues related to collection of race and ethnicity data Issues related to Medicare and Medicaid Issues related to preventative care
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Republican |
| AK |
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE